Global and United States Celecoxib API Market Report & Forecast 2024-2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global and United States Celecoxib API Market Report & Forecast 2024-2034
Celecoxib API refers to the active pharmaceutical ingredient (API) of the drug Celecoxib, which is a non-steroidal anti-inflammatory drug (NSAID) used to relieve pain, inflammation, and stiffness caused by conditions such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. The Celecoxib API is the chemical compound responsible for the therapeutic effects of the drug. It is a selective cyclooxygenase-2 (COX-2) inhibitor, which means it works by blocking the production of prostaglandins, which are chemicals produced by the body in response to injury or inflammation. By reducing the production of prostaglandins, Celecoxib can help relieve pain, reduce inflammation, and improve joint mobility. The Celecoxib API is typically manufactured by pharmaceutical companies in accordance with strict quality control standards to ensure its purity, potency, and safety. It is then used to produce finished dosage forms of Celecoxib, such as tablets or capsules, which are prescribed by healthcare professionals to treat various inflammatory conditions.
Market Analysis and InsightsGlobal and United States Celecoxib API Market
This report focuses on global and United States Celecoxib API market, also covers the segmentation data of other regions in regional level and county level.
The global Celecoxib API revenue was US$ 56 million in 2024 and is forecast to a readjusted size of US$ 82 million by 2034 with a CAGR of 4.9% during the forecast period (2024-2034).
Global key players of celecoxib API include Pfizer, Jiangxi Synergy, ScinoPharm, Jiangsu Hengrui Medicine, Jiangsu Chiatai Qingjiang, etc. The top five players hold a share over 73%. Asia Pacific is the largest market, has a share about 43%, followed by North America and Europe, with share 28% and 25%, separately.
Global Celecoxib API Scope and Market Size
Celecoxib API market is segmented in regional and country, by players, by type and by application. Companies, stakeholders, and other participants in the global Celecoxib API market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by type and by application for the period 2018-2034.
For United States market, this report focuses on the Celecoxib API market size by players, by Type and by Application, for the period 2018-2034. The key players include the global and local players, which play important roles in United States.
Pfizer
Teva Pharmaceuticals
Viatris(Mylan)
ScinoPharm
Jiangxi Synergy
Jiangsu Hengrui Medicine
Jiangsu Chiatai Qingjiang
Hisun Pharmaceutical Nantong
Aurobindo Pharma
Punjab Chemicals
Segment by Type
Standard grade Celecoxib API
Micronized Celecoxib API
Pharmaceutical
Laboratory
By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa
Chapter 1Introduces Celecoxib API definition, global sales (volume and revenue), United States market size, United States percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 2Provides the analysis of various market segments by type, covering the volume, price, revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3Provides the analysis of various market segments by application, covering the revenue, price, volume, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4Detailed analysis of Celecoxib API companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Revenue and volume of Celecoxib API in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 6Americas by type, by application and by country, sales, and revenue for each segment.
Chapter 7EMEA by type, by application and by region, sales, and revenue for each segment.
Chapter 8China by type, by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by type, by application and by region, sales, and revenue for each segment.
Chapter 10Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Celecoxib API sales, revenue, gross margin, and recent development, etc.
Chapter 11Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 12Research findings and conclusion
Market Analysis and InsightsGlobal and United States Celecoxib API Market
This report focuses on global and United States Celecoxib API market, also covers the segmentation data of other regions in regional level and county level.
The global Celecoxib API revenue was US$ 56 million in 2024 and is forecast to a readjusted size of US$ 82 million by 2034 with a CAGR of 4.9% during the forecast period (2024-2034).
Global key players of celecoxib API include Pfizer, Jiangxi Synergy, ScinoPharm, Jiangsu Hengrui Medicine, Jiangsu Chiatai Qingjiang, etc. The top five players hold a share over 73%. Asia Pacific is the largest market, has a share about 43%, followed by North America and Europe, with share 28% and 25%, separately.
Global Celecoxib API Scope and Market Size
Celecoxib API market is segmented in regional and country, by players, by type and by application. Companies, stakeholders, and other participants in the global Celecoxib API market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by type and by application for the period 2018-2034.
For United States market, this report focuses on the Celecoxib API market size by players, by Type and by Application, for the period 2018-2034. The key players include the global and local players, which play important roles in United States.
By Company
Pfizer
Teva Pharmaceuticals
Viatris(Mylan)
ScinoPharm
Jiangxi Synergy
Jiangsu Hengrui Medicine
Jiangsu Chiatai Qingjiang
Hisun Pharmaceutical Nantong
Aurobindo Pharma
Punjab Chemicals
Segment by Type
Standard grade Celecoxib API
Micronized Celecoxib API
Segment by Application
Pharmaceutical
Laboratory
By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa
Chapter Introduction
Chapter 1Introduces Celecoxib API definition, global sales (volume and revenue), United States market size, United States percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 2Provides the analysis of various market segments by type, covering the volume, price, revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3Provides the analysis of various market segments by application, covering the revenue, price, volume, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4Detailed analysis of Celecoxib API companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Revenue and volume of Celecoxib API in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 6Americas by type, by application and by country, sales, and revenue for each segment.
Chapter 7EMEA by type, by application and by region, sales, and revenue for each segment.
Chapter 8China by type, by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by type, by application and by region, sales, and revenue for each segment.
Chapter 10Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Celecoxib API sales, revenue, gross margin, and recent development, etc.
Chapter 11Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 12Research findings and conclusion